ClinicalTrials.gov
ClinicalTrials.gov Menu

BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01788995
Recruitment Status : Active, not recruiting
First Posted : February 11, 2013
Last Update Posted : September 17, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

February 8, 2013
February 11, 2013
September 17, 2018
October 15, 2012
September 30, 2018   (Final data collection date for primary outcome measure)
  • Clinical/demographic patient characteristics at initiation of treatment [ Time Frame: approximately 4 years ]
  • Duration of treatment [ Time Frame: approximately 4 years ]
  • Treatment discontinuations/modifications [ Time Frame: approximately 4 years ]
Same as current
Complete list of historical versions of study NCT01788995 on ClinicalTrials.gov Archive Site
  • Safety: Incidence of adverse events [ Time Frame: approximately 4 years ]
  • Progression-free survival [ Time Frame: approximately 4 years ]
Same as current
Not Provided
Not Provided
 
BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer
A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer
This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma). Newly diagnosed patients who are initiated on carboplatin/paclitaxel chemotherapy in combination with Avastin will be followed for up to 15 months of treatment and 12 months of follow-up.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with newly diagnosed ovarian cancer (epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas) with indication for carboplatin/paclitaxel chemotherapy in combination with Avastin
Ovarian Cancer, Peritoneal Neoplasms
Not Provided
Cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
63
100
September 30, 2018
September 30, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Patients with newly diagnosed advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for first-line carboplatin/paclitaxel chemotherapy in combination with Avastin

Exclusion Criteria:

  • Contraindications for Avastin according to the Summary of Product Characteristics
Sexes Eligible for Study: Female
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT01788995
ML28355
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
September 2018